Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Pyxis Oncology Inc.

In a report released on July 7, Leonid Timashev from RBC Capital maintained a Buy rating on Pyxis Oncology, with a price target of $5.00. The compa...

RBC Capital Reaffirms Their Buy Rating on Pyxis Oncology (PYXS)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Pyxis Oncology (PYXS) and Pfizer (PFE) with bullish ...

Analysts’ Top Healthcare Picks: Pyxis Oncology (PYXS), Pfizer (PFE)

The latest announcement is out from Pyxis Oncology ( ($PYXS) ). Pyxis Oncology entered into definitive securities purchase agreements on June 30, 2...

Pyxis Oncology Raises Capital Through Private Placement Financing

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Pyxis Oncology (PYXS) and Telix Pharmaceuticals (TLPPF). Pyxis On...

Analysts Conflicted on These Healthcare Names: Pyxis Oncology (PYXS) and Telix Pharmaceuticals (OtherTLPPF)

In a report released yesterday, from Guggenheim maintained a Buy rating on Pyxis Oncology, with a price target of $7.00. The company’s shares close...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PYXS	$2.23	-8.23%	413.70K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PYXS	$2.23	-8.2%	413.70K
3
4
5
6

PYXS

PYXS

Get Pyxis Oncology Inc. Data in Excel

Get Pyxis Oncology Inc. Data in Excel